Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis patients: does your injection schedule matter?

NCT ID NCT07642544

Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 120 adults with moderate-to-severe psoriasis who take secukinumab, a biologic drug. It compares two maintenance schedules: the standard every-4-week injection versus a non-standard schedule (longer intervals or lower dose). The goal is to see which schedule keeps psoriasis under control longer and how well patients recover if the drug stops working. The study is observational and uses medical records, so it cannot prove cause and effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
secukinumab (a biologic drug that targets inflammation)
What this could lead to
If successful, this could help doctors choose the best maintenance schedule for secukinumab to keep psoriasis under control longer.
What could go wrong
This is a small, single-center retrospective study, not a randomized trial. Results may not apply to all patients, and the study only looks back at existing records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with moderate-to-severe plaque psoriasis

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis. * Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period. * Achieved PASI 75 response at the end of the induction period. * Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments. * Complete electronic medical record data available for extraction. Exclusion Criteria: * Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period. * Irregular maintenance treatment pattern, or substantial missing data. * Use of other targeted biologic agents or small molecule drugs during the maintenance period. * Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy. * Participation in other interventional clinical trials that may confound efficacy assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis Psoriasis (PSO)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School

    Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.